Aspira Women’s Health to Participate in the Upcoming Investor Conferences

Rhea-AI Summary

Aspira Women’s Health Inc. (Nasdaq: AWH) has announced management participation in two upcoming investor conferences. The MicroCap Rodeo Spring Into Action Conference is scheduled for May 17, 2022 at 12:30pm ET, with a webcast available here. The William Blair 42nd Annual Growth Stock Conference will take place on June 7, 2022, at 8:00am CT (9:00am ET), with a webcast accessible here. One-on-one meetings will also be available on June 7-8.

AUSTIN, Texas, May 12, 2022 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that management will participate in the “MicroCap Rodeo Spring Into Action Best Ideas” Conference virtually and the “William Blair 42^nd Annual Growth Stock Conference” in Chicago. Details for both investor conferences are below:

MicroCap Rodeo Spring Into Action - Best Ideas Conference
Date:	Tuesday, May 17th, 2022
Time:	12:30pm ET
Webcast:	https://www.webcaster4.com/Webcast/Page/2882/45575

Management will host one-on-one virtual meetings on Friday, May 20^th, 2022. To request a meeting, please register here.

William Blair’s 42nd Annual Growth Stock Conference
Date:	Tuesday, June 7th, 2022
Time:	8:00am CT / 9:00am ET
Webcast:	https://wsw.com/webcast/blair66/awh/1768896

Management will also be available for in-person one-on-one meetings at the Loews Chicago Hotel on Tuesday, June 7^th – Wednesday, June 8^th, 2022. To request a meeting, please email growthstockconf@williamblair.com.

About Aspira Women’s Health Inc.
Aspira Women’s Health Inc. is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women. Aspira Women’s Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1plus™ combines our FDA-cleared products, OVA1^® and OVERA^®, to detect risk of ovarian malignancy in women with adnexal masses. Aspira GenetiX™ testing offers both targeted and comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, Aspira Women’s Health is working to deliver a portfolio of pelvic mass products over a patient’s lifetime with our cutting-edge research. The next generation of products in development include OVAWatch™ and EndoCheck™. To improve patient accessibility, Aspira Women’s Health has recently launched our Aspira Synergy™ technology transfer platform to empower health systems, academics, regional labs, and physician group labs to conduct genetic and specialty tests in-house. Visit our website for more information at www.aspirawh.com.

Investor Relations Contact: 
Ashley R. Robinson  
LifeSci Advisors, LLC  
Tel: 617-430-7577 
Arr@lifesciadvisors.com 

FAQ

When will Aspira Women’s Health participate in the MicroCap Rodeo Spring Into Action Conference?

Aspira Women’s Health will participate in the MicroCap Rodeo Spring Into Action Conference on May 17, 2022, at 12:30pm ET.

What is the date and time for the William Blair 42nd Annual Growth Stock Conference?

The William Blair 42nd Annual Growth Stock Conference is on June 7, 2022, at 8:00am CT (9:00am ET).

Where can I find the webcasts for the upcoming Aspira Women’s Health conferences?

The webcast for the MicroCap Rodeo Conference is available here, and for the William Blair Conference, it is available here.

Will there be one-on-one meetings available for investors with Aspira Women’s Health?

Yes, management will host one-on-one virtual meetings on May 20, 2022, and in-person meetings on June 7-8, 2022.

What is Aspira Women’s Health's focus in women's health?

Aspira Women’s Health focuses on innovative testing options and solutions for gynecologic health, particularly in ovarian cancer risk assessment and pelvic diseases.